ClinicalTrials.gg
CompletedNCT05192200Updated Feb 6, 2025Results posted

An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study

A Phase 2 interventional study of Anti-Beta Interferon (PF-06823859) in Dermatomyositis, sponsored by Pfizer. Completed at 25 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-06.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 94 studies in Dermatomyositis with a site in United States — 30 open to participants now, 33 under way, 6 of them phase 3. Dermatomyositis · United States.

Enrollment
38th of 73
24 · median 25
Started
2021
with 3 others
Phase 2
31 of 94
5 open now
Registered
58th of 94
by date
Lead sponsor
4 of 94
Pfizer

Among the 94 studies in Dermatomyositis with a site in United States, this one is the 38th largest by enrollment of the 73 interventional ones that give a count, is one of 4 that started in 2021, is one of 31 in phase 2, and was the 58th registered.

Dermatomyositis

184 studies on the registry are indexed under Dermatomyositis; 63 are open to participants now.

Browse Dermatomyositis studies →

Open to participants now

30 of the 94 studies in Dermatomyositis with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Dermatomyositis studies recruiting now, 24 (48%) set no upper age limit and 16 (32%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Dermatomyositis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research study is to evaluate the long-term safety, and tolerability of PF-06823859 study drug in adult participants with Dermatomyositis (DM) from a qualifying study.

03

Conditions studied

  • Dermatomyositis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants aged ≥18 and ≤80 with moderate to severe dermatomyositis (DM), that have completed the treatment period of a qualifying study.
  • Capable of giving signed .
  • Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study
  • Participants who met discontinuation criteria at any point during the participating qualifying studies.
  • Participants with an ongoing safety event in the qualifying studies which, in the opinion of the investigator or sponsor, is an ongoing safety concern OR the participant has met safety monitoring criteria in the qualifying study that has not resolved.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Anti-Beta Interferon drug (PF-06823859)

    IV infusion

    Drug: Anti-Beta Interferon (PF-06823859)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An Adverse Event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered treatment emergent relative to a given treatment if the event occurred for the first time during the effective duration of treatment and was not seen prior to the start of treatment, or the event was seen prior to the start of treatment but increased in severity during treatment. AEs included both serious adverse events (SAEs) and all non-SAEs.

    Time frame: From Day 1 of dosing maximum up to Week 68

  2. Number of Participants With Laboratory Abnormalities

    Hematology laboratory parameters: hemoglobin (grams per deciliter \[g/dL\]); hematocrit (percentage \[%\]); lymphocytes (10\^3 per (/) millimeter\[mm\]\^3); lymphocytes/leukocytes (%); neutrophils (10\^3/mm\^3) less than (\<)0.8\*lower limit of normal (LLN), leukocytes (10\^3/mm\^3) \<0.6\*LLN, neutrophils (10\^3/mm\^3); basophils (10\^3/mm\^3); basophils/leukocytes (%); monocytes/leukocytes (%); activated partial thromboplastin time (seconds \[sec\]); prothrombin time (sec) more than (\>)1.2\*upper limit of normal (ULN). Clinical chemistry: potassium (milliequivalents per liter \[mEq/L\]); bicarbonate (mEq/L) \<0.9\*LLN, creatine kinase (units per liter \[U/L\]) \>2.0\*ULN, glucose (milligram per deciliter \[mg/dl\]); glucose-fasting (mg/dl) \>1.5\*ULN. Urinalysis: Urine glucose; ketones; urine protein; urine hemoglobin; nitrite; leukocyte esterase; hyaline casts (1/per leukocytosis promoting factor (more than or equal to \[\>=\] 1, urine erythrocytes (scalar); urine leukocytes (scalar) \>=20.

    Time frame: From Day 1 of dosing maximum up to Week 68

  3. Number of Participants According to Categorization of Changes in Vital Signs

    Vital signs included the following parameters: sitting diastolic blood pressure (millimetres of mercury \[mmHg\]) change \>=20 mmHg increase; sitting systolic blood pressure (mmHg) change \>=30 mmHg increase, sitting diastolic blood pressure (mmHg) change \>=20 mmHg decrease and sitting systolic blood pressure (mmHg) change \>=30 mmHg decrease.

    Time frame: From Day 1 of dosing maximum up to Week 68

  4. Number of Participants According to Categorization of Electrocardiogram (ECG) Findings

    ECG parameters evaluated were: PR interval value \>=300 milliseconds (msec); QRS duration value \>=200 msec; QT interval value \>=500 msec; corrected QT Interval using Fridericia's formula (QTCF) 450 less than or equal to (\<=) value \<480 msec, 480 \<=value\<500 msec and value\>=500 msec.

    Time frame: From Day 1 of dosing maximum up to Week 68

Secondary outcomes

  1. Change From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 52

    CDASI is a validated DM-specific instrument designed to systematically quantify the extent of cutaneous disease. Disease involvement in 15 different anatomical locations was rated using three activity (erythema, scale, erosion/ulceration) and two damage (poikiloderma, calcinosis) measures. The presence and severity of Gottron's papules, periungual changes and alopecia were also captured. Total CDASI activity score was based on the physician's evaluation of three activities (erythema, scale, erosion/ulceration), presence and severity of Gottron's papules, periungual changes and alopecia. Total CDASI activity score ranged from 0 to 100, where higher scores indicated higher levels of disability.

    Time frame: Baseline (before dose 1), Week 52

  2. Change From Baseline in CDASI Activity Score at Weeks 12, 24, 36, and 48

    CDASI is a validated DM-specific instrument designed to systematically quantify the extent of cutaneous disease. Disease involvement in 15 different anatomical locations was rated using three activity (erythema, scale, erosion/ulceration) and two damage (poikiloderma, calcinosis) measures. The presence and severity of Gottron's papules, periungual changes and alopecia were also captured. Total CDASI activity score was based on the physician's evaluation of three activities (erythema, scale, erosion/ulceration), presence and severity of Gottron's papules, periungual changes and alopecia. Total CDASI activity score ranged from 0 to 100, where higher scores indicated higher levels of disability.

    Time frame: Baseline (before dose 1), Weeks 12, 24, 36 and 48

  3. Absolute Values of CDASI Activity Score at Weeks 12, 24, 36, 48, and 52

    CDASI is a validated DM-specific instrument designed to systematically quantify the extent of cutaneous disease. Disease involvement in 15 different anatomical locations was rated using three activity (erythema, scale, erosion/ulceration) and two damage (poikiloderma, calcinosis) measures. The presence and severity of Gottron's papules, periungual changes and alopecia were also captured. Total CDASI activity score was based on the physician's evaluation of three activities (erythema, scale, erosion/ulceration), presence and severity of Gottron's papules, periungual changes and alopecia. Total CDASI activity score ranged from 0 to 100, where higher scores indicated higher levels of disability.

    Time frame: Weeks 12, 24, 36, 48 and 52

  4. Change From Baseline in CDASI Damage Score at Weeks 12, 24, 36, 48, and 52

    CDASI is a validated DM-specific instrument designed to systematically quantify the extent of cutaneous disease. Disease involvement in 15 different anatomical locations was rated using three activity (erythema, scale, erosion/ulceration) and two damage (poikiloderma, calcinosis) measures. The presence and severity of Gottron's papules, periungual changes and alopecia were also captured. Total CDASI damage score was based on the physician's evaluation of two damage (poikiloderma, calcinosis) measures, and presence and severity of Gottron's papules. Total CDASI damage score ranged from 0 to 32, where higher scores indicated higher level of skin damage.

    Time frame: Baseline (before dose on Day 1), Weeks 12, 24, 36, 48 and 52

  5. Absolute Values of CDASI Damage Score at Weeks 12, 24, 36, 48, and 52

    CDASI is a validated DM-specific instrument designed to systematically quantify the extent of cutaneous disease. Disease involvement in 15 different anatomical locations was rated using three activity (erythema, scale, erosion/ulceration) and two damage (poikiloderma, calcinosis) measures. The presence and severity of Gottron's papules, periungual changes and alopecia were also captured. Total CDASI damage score was based on the physician's evaluation of two damage (poikiloderma, calcinosis) measures, and presence and severity of Gottron's papules. Total CDASI damage score ranged from 0 to 32, where higher scores indicated higher level of skin damage.

    Time frame: Weeks 12, 24, 36, 48 and 52

  6. Total Improvement Score (TIS) at Weeks 12, 24, 36, 48 and 52: Muscle Cohort

    There are 6 core set measure that comprised of TIS: 1) Physician Global Assessment Score \[PhGA\] (from Myositis Disease Activity Assessment Tool \[MDAAT\], 0-100 mm or 0-10 centimeter (cm) on visual analogue scale \[VAS\], higher scores= worse health status); 2) Patient Global Assessment Score \[PtGA\] (0-100 mm or 0-10 cm on VAS, higher scores= worse status); 3) Manual Muscle Testing-8 (MMT-8) designated muscle groups (0-80, lower scores= higher level of disability); 4) Health Assessment Questionnaire Disability Index \[HAQ-DI\] (0-3, higher scores= worse status); 5) Global Extramuscular Disease Activity (from MDAAT, 0-10 cm on a VAS, higher scores= higher level of disability); 6) Participant's most elevated muscle enzymes. TIS was sum of all 6 improvement scores associated with the change in each core set measure. TIS ranged from 0 to 100; where TIS\>=20 shows minimal improvement, TIS \>=40 shows moderate improvement and TIS \>= 60 shows major improvement.

    Time frame: Weeks 12, 24, 36, 48 and 52

  7. Change From Baseline in Physician Global Assessment (PhGA) Score at Week 12, 24, 36, 48 and 52: Muscle Cohort

    PhGA: Investigator was asked to evaluate the participant's overall disease activity on a VAS of 0 cm (very good) to 10 cm (very poor), higher scores indicated worse health status.

    Time frame: Baseline (before dose on day 1), Weeks 12, 24, 36, 48 and 52

  8. Change From Baseline in Patient Global Assessment (PtGA) Score at Weeks 12, 24, 36, 48 and 52: Muscle Cohort

    PtGA was the assessment of the severity of disease by the participant/participant's guardian, using a VAS from 0 mm (no evidence of disease activity) to 100 mm (extremely active or severe disease activity). Higher score indicated worse status.

    Time frame: Baseline (before dose on day 1), Weeks 12, 24, 36, 48 and 52

  9. Change From Baseline in Manual Muscle Testing-8 Designated Muscle Groups (MMT-8) Score at Weeks 12, 24, 36, 48 and 52: Muscle Cohort

    MMT-8 is a tool that assesses muscle strength using manual muscle testing. Eight designated muscles are tested unilaterally with a total potential summed score of 0-80. Lower scores indicated a higher level of disability.

    Time frame: Baseline (before dose on day 1), Weeks 12, 24, 36, 48 and 52

  10. Change From Baseline in Health Assessment Questionnaire and Disease Index (HAQ-DI) Score at Weeks 12, 24, 36, 48 and 52: Muscle Cohort

    HAQ-DI consisted of eight sections (including dressing \& grooming, arising, eating, walking, hygiene, grip, reach, and activities). Each section had multiple questions that the participant used to rank their functionality and ranged from 0 to 3 where 0 = without any difficulty and 3 = unable to do. For each participant, the average ranking was calculated for each of the eight sections. HAQ-DI had a score range of 0 to 3, where higher score reflected worse status.

    Time frame: Baseline (before dose on day 1), Weeks 12, 24, 36, 48 and 52

  11. Change From Baseline in Creatine Kinase at Weeks 12, 24, 36, 48 and 52: Muscle Cohort

    Creatine kinase is a muscle enzyme measured in units per liter (U/L).

    Time frame: Baseline (before dose on day 1), Weeks 12, 24, 36, 48 and 52

  12. Change From Baseline in Extramuscular Global Assessment From the Myositis Disease Activity Assessment Tool (MDAAT) Score at Weeks 12, 24, 36, 48 and 52: Muscle Cohort

    MDAAT tool measures the degree of disease activity of extramuscular organ systems and muscle on a VAS of 0 to 10 cm, higher scores indicated higher level of disability.

    Time frame: Baseline (before dose on day 1), Weeks 12, 24, 36, 48 and 52

07

Results

Posted Feb 6, 2025

Participant flow

Eligible participants with moderate to severe dermatomyositis (DM) who completed the treatment period of qualifying study C0251002 \[NCT03181893\] and had agreement from their study doctor to continue active treatment were enrolled in this study. A total of 24 participants (9 participants from the skin predominant cohort \[Amended stage 2\] and 15 participants from the muscle predominant cohort \[Stage 3\]) of the study C0251002 were enrolled in this open label, long-term extension (OLE) study.

Treatment Period
Participant flow — Treatment Period
MilestonePF-06823859 600mg: All Participants
Started24
Safety analysis set24
Skin analysis set9
Muscle analysis set15
Completed21
Not completed3
Withdrew: Other1
Withdrew: Lack of efficacy1
Withdrew: Withdrawal by subject1
Follow-up
Participant flow — Follow-up
MilestonePF-06823859 600mg: All Participants
Started22
Completed21
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An Adverse Event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered treatment emergent relative to a given treatment if the event occurred for the first time during the effective duration of treatment and was not seen prior to the start of treatment, or the event was seen prior to the start of treatment but increased in severity during treatment. AEs included both serious adverse events (SAEs) and all non-SAEs.

Time frame:
From Day 1 of dosing maximum up to Week 68
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsPF-06823859 600mg: Skin CohortPF-06823859 600mg: Muscle CohortPF-06823859 600mg: All Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)71320
PrimaryNumber of Participants With Laboratory Abnormalities

Hematology laboratory parameters: hemoglobin (grams per deciliter \[g/dL\]); hematocrit (percentage \[%\]); lymphocytes (10\^3 per (/) millimeter\[mm\]\^3); lymphocytes/leukocytes (%); neutrophils (10\^3/mm\^3) less than (\<)0.8\*lower limit of normal (LLN), leukocytes (10\^3/mm\^3) \<0.6\*LLN, neutrophils (10\^3/mm\^3); basophils (10\^3/mm\^3); basophils/leukocytes (%); monocytes/leukocytes (%); activated partial thromboplastin time (seconds \[sec\]); prothrombin time (sec) more than (\>)1.2\*upper limit of normal (ULN). Clinical chemistry: potassium (milliequivalents per liter \[mEq/L\]); bicarbonate (mEq/L) \<0.9\*LLN, creatine kinase (units per liter \[U/L\]) \>2.0\*ULN, glucose (milligram per deciliter \[mg/dl\]); glucose-fasting (mg/dl) \>1.5\*ULN. Urinalysis: Urine glucose; ketones; urine protein; urine hemoglobin; nitrite; leukocyte esterase; hyaline casts (1/per leukocytosis promoting factor (more than or equal to \[\>=\] 1, urine erythrocytes (scalar); urine leukocytes (scalar) \>=20.

Time frame:
From Day 1 of dosing maximum up to Week 68
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities
ParticipantsPF-06823859 600mg: Skin CohortPF-06823859 600mg: Muscle CohortPF-06823859 600mg: All Participants
Number of Participants With Laboratory Abnormalities81422
PrimaryNumber of Participants According to Categorization of Changes in Vital Signs

Vital signs included the following parameters: sitting diastolic blood pressure (millimetres of mercury \[mmHg\]) change \>=20 mmHg increase; sitting systolic blood pressure (mmHg) change \>=30 mmHg increase, sitting diastolic blood pressure (mmHg) change \>=20 mmHg decrease and sitting systolic blood pressure (mmHg) change \>=30 mmHg decrease.

Time frame:
From Day 1 of dosing maximum up to Week 68
Reported as:
Count of participants · Participants
Number of Participants According to Categorization of Changes in Vital Signs
ParticipantsPF-06823859 600mg: Skin CohortPF-06823859 600mg: Muscle CohortPF-06823859 600mg: All Participants
Increase: sitting diastolic blood pressure (mmHg)448
Increase: sitting systolic blood pressure (mmHg)426
Decrease: sitting diastolic blood pressure (mmHg)145
Decrease: sitting systolic blood pressure (mmHg)134
PrimaryNumber of Participants According to Categorization of Electrocardiogram (ECG) Findings

ECG parameters evaluated were: PR interval value \>=300 milliseconds (msec); QRS duration value \>=200 msec; QT interval value \>=500 msec; corrected QT Interval using Fridericia's formula (QTCF) 450 less than or equal to (\<=) value \<480 msec, 480 \<=value\<500 msec and value\>=500 msec.

Time frame:
From Day 1 of dosing maximum up to Week 68
Reported as:
Count of participants · Participants
Number of Participants According to Categorization of Electrocardiogram (ECG) Findings
ParticipantsPF-06823859 600mg: Skin CohortPF-06823859 600mg: Muscle CohortPF-06823859 600mg: All Participants
PR interval: value >=300 msec000
QRS duration: value >=200 msec000
QT interval: >=500 msec000
QTCF: 450<=value<480 msec213
QTCF: 480<=value<500 msec000
QTCF: value>=500 msec000
SecondaryChange From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 52

CDASI is a validated DM-specific instrument designed to systematically quantify the extent of cutaneous disease. Disease involvement in 15 different anatomical locations was rated using three activity (erythema, scale, erosion/ulceration) and two damage (poikiloderma, calcinosis) measures. The presence and severity of Gottron's papules, periungual changes and alopecia were also captured. Total CDASI activity score was based on the physician's evaluation of three activities (erythema, scale, erosion/ulceration), presence and severity of Gottron's papules, periungual changes and alopecia. Total CDASI activity score ranged from 0 to 100, where higher scores indicated higher levels of disability.

Time frame:
Baseline (before dose 1), Week 52
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 52
Units on a scalePF-06823859 600mg: Skin CohortPF-06823859 600mg: Muscle Cohort
Change From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 52-4.67 (-7.41 to -1.92)-2.51 (-3.40 to -1.62)
SecondaryChange From Baseline in CDASI Activity Score at Weeks 12, 24, 36, and 48

CDASI is a validated DM-specific instrument designed to systematically quantify the extent of cutaneous disease. Disease involvement in 15 different anatomical locations was rated using three activity (erythema, scale, erosion/ulceration) and two damage (poikiloderma, calcinosis) measures. The presence and severity of Gottron's papules, periungual changes and alopecia were also captured. Total CDASI activity score was based on the physician's evaluation of three activities (erythema, scale, erosion/ulceration), presence and severity of Gottron's papules, periungual changes and alopecia. Total CDASI activity score ranged from 0 to 100, where higher scores indicated higher levels of disability.

Time frame:
Baseline (before dose 1), Weeks 12, 24, 36 and 48
Reported as:
Least squares mean · Units on a scale
Change From Baseline in CDASI Activity Score at Weeks 12, 24, 36, and 48
Units on a scalePF-06823859 600mg: Skin CohortPF-06823859 600mg: Muscle Cohort
Change at Week 12-5.28 (-7.67 to -2.90)-0.87 (-1.98 to 0.25)
Change at Week 24-4.11 (-6.47 to -1.75)-0.67 (-2.09 to 0.75)
Change at Week 36-4.51 (-7.90 to -1.11)-1.40 (-2.40 to -0.40)
Change at Week 48-4.56 (-7.27 to -1.84)-1.70 (-2.70 to -0.70)
SecondaryAbsolute Values of CDASI Activity Score at Weeks 12, 24, 36, 48, and 52

CDASI is a validated DM-specific instrument designed to systematically quantify the extent of cutaneous disease. Disease involvement in 15 different anatomical locations was rated using three activity (erythema, scale, erosion/ulceration) and two damage (poikiloderma, calcinosis) measures. The presence and severity of Gottron's papules, periungual changes and alopecia were also captured. Total CDASI activity score was based on the physician's evaluation of three activities (erythema, scale, erosion/ulceration), presence and severity of Gottron's papules, periungual changes and alopecia. Total CDASI activity score ranged from 0 to 100, where higher scores indicated higher levels of disability.

Time frame:
Weeks 12, 24, 36, 48 and 52
Reported as:
Mean · Units on a scale
Absolute Values of CDASI Activity Score at Weeks 12, 24, 36, 48, and 52
Units on a scalePF-06823859 600mg: Skin CohortPF-06823859 600mg: Muscle Cohort
Week 124.4 ± 2.454.4 ± 3.44
Week 245.0 ± 3.714.6 ± 3.81
Week 365.5 ± 5.133.9 ± 3.27
Week 484.6 ± 4.453.1 ± 3.03
Week 524.4 ± 4.852.2 ± 2.52
SecondaryChange From Baseline in CDASI Damage Score at Weeks 12, 24, 36, 48, and 52

CDASI is a validated DM-specific instrument designed to systematically quantify the extent of cutaneous disease. Disease involvement in 15 different anatomical locations was rated using three activity (erythema, scale, erosion/ulceration) and two damage (poikiloderma, calcinosis) measures. The presence and severity of Gottron's papules, periungual changes and alopecia were also captured. Total CDASI damage score was based on the physician's evaluation of two damage (poikiloderma, calcinosis) measures, and presence and severity of Gottron's papules. Total CDASI damage score ranged from 0 to 32, where higher scores indicated higher level of skin damage.

Time frame:
Baseline (before dose on Day 1), Weeks 12, 24, 36, 48 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in CDASI Damage Score at Weeks 12, 24, 36, 48, and 52
Units on a scalePF-06823859 600mg: Skin CohortPF-06823859 600mg: Muscle Cohort
Change at Week 12-2.4 ± 2.77-0.8 ± 1.15
Change at Week 24-1.8 ± 2.33-0.5 ± 1.19
Change at Week 36-2.3 ± 2.25-0.5 ± 1.06
Change at Week 48-2.0 ± 2.00-0.9 ± 1.24
Change at Week 52-2.1 ± 2.09-0.9 ± 1.08
SecondaryAbsolute Values of CDASI Damage Score at Weeks 12, 24, 36, 48, and 52

CDASI is a validated DM-specific instrument designed to systematically quantify the extent of cutaneous disease. Disease involvement in 15 different anatomical locations was rated using three activity (erythema, scale, erosion/ulceration) and two damage (poikiloderma, calcinosis) measures. The presence and severity of Gottron's papules, periungual changes and alopecia were also captured. Total CDASI damage score was based on the physician's evaluation of two damage (poikiloderma, calcinosis) measures, and presence and severity of Gottron's papules. Total CDASI damage score ranged from 0 to 32, where higher scores indicated higher level of skin damage.

Time frame:
Weeks 12, 24, 36, 48 and 52
Reported as:
Mean · Units on a scale
Absolute Values of CDASI Damage Score at Weeks 12, 24, 36, 48, and 52
Units on a scalePF-06823859 600mg: Skin CohortPF-06823859 600mg: Muscle Cohort
Week 120.9 ± 1.251.6 ± 3.07
Week 241.9 ± 2.261.9 ± 3.41
Week 361.4 ± 2.331.9 ± 3.43
Week 481.7 ± 2.121.3 ± 2.83
Week 521.6 ± 1.591.3 ± 3.19
SecondaryTotal Improvement Score (TIS) at Weeks 12, 24, 36, 48 and 52: Muscle Cohort

There are 6 core set measure that comprised of TIS: 1) Physician Global Assessment Score \[PhGA\] (from Myositis Disease Activity Assessment Tool \[MDAAT\], 0-100 mm or 0-10 centimeter (cm) on visual analogue scale \[VAS\], higher scores= worse health status); 2) Patient Global Assessment Score \[PtGA\] (0-100 mm or 0-10 cm on VAS, higher scores= worse status); 3) Manual Muscle Testing-8 (MMT-8) designated muscle groups (0-80, lower scores= higher level of disability); 4) Health Assessment Questionnaire Disability Index \[HAQ-DI\] (0-3, higher scores= worse status); 5) Global Extramuscular Disease Activity (from MDAAT, 0-10 cm on a VAS, higher scores= higher level of disability); 6) Participant's most elevated muscle enzymes. TIS was sum of all 6 improvement scores associated with the change in each core set measure. TIS ranged from 0 to 100; where TIS\>=20 shows minimal improvement, TIS \>=40 shows moderate improvement and TIS \>= 60 shows major improvement.

Time frame:
Weeks 12, 24, 36, 48 and 52
Reported as:
Least squares mean · Units on a scale
Total Improvement Score (TIS) at Weeks 12, 24, 36, 48 and 52: Muscle Cohort
Units on a scalePF-06823859 600mg: Muscle Cohort
Week 1215.03 (8.36 to 21.70)
Week 2415.67 (8.96 to 22.37)
Week 3618.17 (10.84 to 25.49)
Week 4819.61 (10.58 to 28.63)
Week 5223.66 (14.05 to 33.28)
SecondaryChange From Baseline in Physician Global Assessment (PhGA) Score at Week 12, 24, 36, 48 and 52: Muscle Cohort

PhGA: Investigator was asked to evaluate the participant's overall disease activity on a VAS of 0 cm (very good) to 10 cm (very poor), higher scores indicated worse health status.

Time frame:
Baseline (before dose on day 1), Weeks 12, 24, 36, 48 and 52
Reported as:
Least squares mean · centimeter
Change From Baseline in Physician Global Assessment (PhGA) Score at Week 12, 24, 36, 48 and 52: Muscle Cohort
centimeterPF-06823859 600mg: Muscle Cohort
Change at Week 120.17 (-0.54 to 0.87)
Change at Week 240.29 (-0.39 to 0.98)
Change at Week 36-0.18 (-0.59 to 0.23)
Change at Week 48-0.48 (-0.85 to -0.10)
Change at Week 52-0.60 (-0.97 to -0.23)
SecondaryChange From Baseline in Patient Global Assessment (PtGA) Score at Weeks 12, 24, 36, 48 and 52: Muscle Cohort

PtGA was the assessment of the severity of disease by the participant/participant's guardian, using a VAS from 0 mm (no evidence of disease activity) to 100 mm (extremely active or severe disease activity). Higher score indicated worse status.

Time frame:
Baseline (before dose on day 1), Weeks 12, 24, 36, 48 and 52
Reported as:
Least squares mean · millimeter
Change From Baseline in Patient Global Assessment (PtGA) Score at Weeks 12, 24, 36, 48 and 52: Muscle Cohort
millimeterPF-06823859 600mg: Muscle Cohort
Change at Week 123.70 (-6.55 to 13.95)
Change at Week 24-9.63 (-18.18 to -1.08)
Change at Week 36-9.10 (-16.47 to -1.73)
Change at Week 48-8.36 (-14.74 to -1.97)
Change at Week 52-6.28 (-16.79 to 4.22)
SecondaryChange From Baseline in Manual Muscle Testing-8 Designated Muscle Groups (MMT-8) Score at Weeks 12, 24, 36, 48 and 52: Muscle Cohort

MMT-8 is a tool that assesses muscle strength using manual muscle testing. Eight designated muscles are tested unilaterally with a total potential summed score of 0-80. Lower scores indicated a higher level of disability.

Time frame:
Baseline (before dose on day 1), Weeks 12, 24, 36, 48 and 52
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Manual Muscle Testing-8 Designated Muscle Groups (MMT-8) Score at Weeks 12, 24, 36, 48 and 52: Muscle Cohort
Units on a scalePF-06823859 600mg: Muscle Cohort
Change at Week 12-0.06 (-5.93 to 5.82)
Change at Week 241.85 (-3.11 to 6.81)
Change at Week 364.92 (0.61 to 9.22)
Change at Week 488.00 (5.69 to 10.30)
Change at Week 529.84 (7.38 to 12.31)
SecondaryChange From Baseline in Health Assessment Questionnaire and Disease Index (HAQ-DI) Score at Weeks 12, 24, 36, 48 and 52: Muscle Cohort

HAQ-DI consisted of eight sections (including dressing \& grooming, arising, eating, walking, hygiene, grip, reach, and activities). Each section had multiple questions that the participant used to rank their functionality and ranged from 0 to 3 where 0 = without any difficulty and 3 = unable to do. For each participant, the average ranking was calculated for each of the eight sections. HAQ-DI had a score range of 0 to 3, where higher score reflected worse status.

Time frame:
Baseline (before dose on day 1), Weeks 12, 24, 36, 48 and 52
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Health Assessment Questionnaire and Disease Index (HAQ-DI) Score at Weeks 12, 24, 36, 48 and 52: Muscle Cohort
Units on a scalePF-06823859 600mg: Muscle Cohort
Change at Week 120.00 (-0.13 to 0.13)
Change at Week 24-0.10 (-0.21 to 0.01)
Change at Week 36-0.07 (-0.23 to 0.08)
Change at Week 48-0.12 (-0.24 to 0.00)
Change at Week 52-0.18 (-0.32 to -0.04)
SecondaryChange From Baseline in Creatine Kinase at Weeks 12, 24, 36, 48 and 52: Muscle Cohort

Creatine kinase is a muscle enzyme measured in units per liter (U/L).

Time frame:
Baseline (before dose on day 1), Weeks 12, 24, 36, 48 and 52
Reported as:
Least squares mean · Units per liter
Change From Baseline in Creatine Kinase at Weeks 12, 24, 36, 48 and 52: Muscle Cohort
Units per literPF-06823859 600mg: Muscle Cohort
Change at Week 12-98.93 (-163.76 to -34.11)
Change at Week 24-58.53 (-127.24 to 10.17)
Change at Week 36-97.62 (-150.82 to -44.42)
Change at Week 48-72.04 (-161.48 to 17.39)
Change at Week 52-94.04 (-147.13 to -40.95)
SecondaryChange From Baseline in Extramuscular Global Assessment From the Myositis Disease Activity Assessment Tool (MDAAT) Score at Weeks 12, 24, 36, 48 and 52: Muscle Cohort

MDAAT tool measures the degree of disease activity of extramuscular organ systems and muscle on a VAS of 0 to 10 cm, higher scores indicated higher level of disability.

Time frame:
Baseline (before dose on day 1), Weeks 12, 24, 36, 48 and 52
Reported as:
Least squares mean · centimeter
Change From Baseline in Extramuscular Global Assessment From the Myositis Disease Activity Assessment Tool (MDAAT) Score at Weeks 12, 24, 36, 48 and 52: Muscle Cohort
centimeterPF-06823859 600mg: Muscle Cohort
Change at Week 120.05 (-0.40 to 0.50)
Change at Week 240.23 (-0.23 to 0.68)
Change at Week 360.01 (-0.51 to 0.53)
Change at Week 48-0.16 (-0.91 to 0.59)
Change at Week 52-0.56 (-1.07 to -0.06)

Adverse events

Collected over From Day 1 of dosing maximum up to Week 68. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-06823859 600mg: Skin Cohort0/9 (0%)1/9 (11.1%)7/9 (77.8%)
PF-06823859 600mg: Muscle Cohort0/15 (0%)2/15 (13.3%)13/15 (86.7%)
PF-06823859 600mg: All Participants0/24 (0%)3/24 (12.5%)20/24 (83.3%)
Most frequent serious events
Most frequent serious events
EventPF-06823859 600mg: Skin CohortPF-06823859 600mg: Muscle CohortPF-06823859 600mg: All Participants
Lower limb fractureInjury, poisoning and procedural complications1/90/151/24
CholelithiasisHepatobiliary disorders0/91/151/24
Diabetic ketoacidosisMetabolism and nutrition disorders0/91/151/24
Most frequent other events
Showing 10 of 67
Most frequent other events
EventPF-06823859 600mg: Skin CohortPF-06823859 600mg: Muscle CohortPF-06823859 600mg: All Participants
COVID-19Infections and infestations3/93/156/24
Upper respiratory tract infectionInfections and infestations2/90/152/24
CoughRespiratory, thoracic and mediastinal disorders2/90/152/24
Abdominal painGastrointestinal disorders0/92/152/24
Urinary tract infectionInfections and infestations1/92/153/24
Pain in extremityMusculoskeletal and connective tissue disorders0/92/152/24
HeadacheNervous system disorders0/92/152/24
AnaemiaBlood and lymphatic system disorders1/91/152/24
PalpitationsCardiac disorders1/90/151/24
DiarrhoeaGastrointestinal disorders1/90/151/24

Baseline characteristics

Safety analysis set included all participants enrolled who took at least 1 dose of study intervention. This included all such participants regardless of which stage the participant entered from. Baseline as planned was presented for all participants/safety analysis set, skin cohort/analysis set and muscle cohort/analysis set.

Age, Continuous
Age, Continuous(Years)PF-06823859 600mg: All Participants
All Participants49.79 ± 12.73
Skin Cohort51.78 ± 10.32
Muscle Cohort48.60 ± 14.19
Sex: Female, Male
Sex: Female, Male(Participants)PF-06823859 600mg: All Participants
All Participants — Female20
All Participants — Male4
Skin Cohort — Female9
Skin Cohort — Male0
Muscle Cohort — Female11
Muscle Cohort — Male4
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PF-06823859 600mg: All Participants
All Participants — Hispanic or Latino5
All Participants — Not Hispanic or Latino19
All Participants — Unknown or Not Reported0
Skin Cohort — Hispanic or Latino1
Skin Cohort — Not Hispanic or Latino8
Skin Cohort — Unknown or Not Reported0
Muscle Cohort — Hispanic or Latino4
Muscle Cohort — Not Hispanic or Latino11
Muscle Cohort — Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PF-06823859 600mg: All Participants
All Participants — American Indian or Alaska Native0
All Participants — Asian0
All Participants — Native Hawaiian or Other Pacific Islander0
All Participants — Black or African American0
All Participants — White24
All Participants — More than one race0
All Participants — Unknown or Not Reported0
Skin Cohort — American Indian or Alaska Native0
Skin Cohort — Asian0
Skin Cohort — Native Hawaiian or Other Pacific Islander0
Skin Cohort — Black or African American0
Skin Cohort — White9
Skin Cohort — More than one race0
Skin Cohort — Unknown or Not Reported0
Muscle Cohort — American Indian or Alaska Native0
Muscle Cohort — Asian0
Muscle Cohort — Native Hawaiian or Other Pacific Islander0
Muscle Cohort — Black or African American0
Muscle Cohort — White15
Muscle Cohort — More than one race0
Muscle Cohort — Unknown or Not Reported0
08

Study locations

25 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • University of Alabama at Birmingham, Department of Dermatology
    Birmingham, Alabama 35294, United States
  • Mayo Clinic
    Scottsdale, Arizona 85259, United States
  • Attune Health Research Inc.
    Beverly Hills, California 90211, United States
  • Mayo Clinic in Florida
    Jacksonville, Florida 32224, United States
  • KU Clinical Research Center - Clinical and Translational Science Unit (CTSU)
    Fairway, Kansas 66205, United States
  • KU Clinical and Translational Science Unit (CTSU) Rainbow
    Kansas City, Kansas 66160, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
  • Brigham and Women's Hospital - CTH
    Boston, Massachusetts 02115, United States
  • Center for Outpatient Health
    Saint Louis, Missouri 63108, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63108, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • NYU Grossman School of Medicine, The Ronald O. Perelman Department of Dermatology
    New York, New York 10016, United States
  • NYU Langone Health Clinical Research Center
    New York, New York 10016, United States
  • NYU Langone Radiology - Ambulatory Care Center East 41st Street
    New York, New York 10017, United States
  • Mount Sinai Doctors Dermatology
    New York, New York 10028, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Center for Human Phenomic Science
    Philadelphia, Pennsylvania 19104, United States
  • University of Pennsylvania, Perelman Center for Advanced Medicine (PCAM)
    Philadelphia, Pennsylvania 19104, United States
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, 4032, Hungary
  • Nova Reuma Społka Partnerska
    Białystok, Podlaskie 15-707, Poland
  • Centrum Medyczne Plejady
    Krakow, 30-363, Poland
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Nov 2023, 23 months.

Results were first posted in Feb 2025, 1 year 2 months after primary completion.

Of 19 phase 2 interventional studies under Dermatomyositis, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 52. This study's 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2021
First posted
Jan 14, 2022
StartActual
Dec 20, 2021
Primary completionActual
Nov 20, 2023
CompletionActual
Nov 20, 2023
Results first posted
Feb 6, 2025
Last update
Feb 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05192200
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 14, 2022
Start date
Dec 20, 2021
Primary completion
Nov 20, 2023
Completion
Nov 20, 2023
Results posted
Feb 6, 2025
Last update
Feb 6, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dazukibart

Start the discussion